Riverview Trust Company’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-176
| Closed | -$19.5K | – | 454 |
|
|
2025
Q1 | $19.5K | Sell |
176
-5
| -3% | -$553 | 0.02% | 437 |
|
|
2024
Q4 | $24.7K | Buy |
181
+5
| +3% | +$683 | 0.02% | 381 |
|
|
2024
Q3 | $20.3K | Hold |
176
| – | – | 0.02% | 470 |
|
|
2024
Q2 | $24.2K | Hold |
176
| – | – | 0.02% | 366 |
|
|
2024
Q1 | $24.3K | Buy |
+176
| New | +$24.3K | 0.02% | 403 |
|
|
2023
Q4 | – | Sell |
-176
| Closed | -$19.8K | – | 449 |
|
|
2023
Q3 | $19.8K | Hold |
176
| – | – | 0.02% | 382 |
|
|
2023
Q2 | $16.6K | Hold |
176
| – | – | 0.02% | 446 |
|
|
2023
Q1 | $17.8K | Hold |
176
| – | – | 0.02% | 389 |
|
|
2022
Q4 | $21K | Hold |
176
| – | – | 0.02% | 329 |
|
|
2022
Q3 | $19K | Hold |
176
| – | – | 0.02% | 373 |
|
|
2022
Q2 | $17K | Hold |
176
| – | – | 0.01% | 441 |
|
|
2022
Q1 | $17K | Buy |
+176
| New | +$17K | 0.01% | 563 |
|